OTC: CHGCF - Chugai Pharmaceutical Co., Ltd.

Rentabilidade por seis meses: -7.47%
Rendimento de dividendos: +2.96%
Setor: Healthcare

Cronograma de promoção Chugai Pharmaceutical Co., Ltd.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

mais detalhes
It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета jpy
Див.доход ао 3.38
Дивиденд ао 1.13
Сайт https://www.chugai-pharm.co.jp
Цена ао 49.11
Alteração de preço por dia: 0% (44.23)
Alteração de preço por semana: +1.24% (43.69)
Alteração de preço por mês: -14.28% (51.6)
Alteração de preço em 3 meses: +3.73% (42.64)
Mudança de preço em seis meses: -7.47% (47.8)
Mudança de preço por ano: +13% (39.14)
Mudança de preço desde o início do ano: -5.27% (46.69)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 7.8 1
P/BV 5.33 2
P/E 26.64 6
EV/EBITDA 18.38 6
Total: 5.38

Eficiência

Nome Significado Nota
ROA, % 16.84 5
ROE, % 20.02 7
Total: 6.33

Dividendos

Nome Significado Nota
Div yield, % 2.96 7.4
DSI 0.9286 9.29
Total: 6.03

Obrigação

Nome Significado Nota
Debt/EBITDA 0.0301 10
Total: 9.6

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 61.96 8
Rentabilidade Ebitda, % 113.37 10
Rentabilidade EPS, % 106.17 10
Total: 9.6
Mais detalhes

Mais detalhes



Supervisor Cargo Pagamento Ano de nascimento
Dr. Osamu Okuda President, CEO & Chairman 1.44M 1963 (62 ano)
Toshiya Sasai Executive of Investor Relations Group & Corporate Communications Department N/A
Mr. Shinji Hidaka Executive Vice President N/A
Mr. Junichi Ebihara Executive Vice President N/A
Dr. Yoshiaki Ohashi Senior VP & Full-time Audit Supervisory Board Member N/A 1960 (65 anos)
Mr. Tetsuya Yamaguchi Executive VP & Head of PHC Solution Unit N/A
Mr. Yoshiyuki Yano Executive Vice President N/A
Mr. Iwaaki Taniguchi Executive VP, Head of Finance Supervisory Division, CFO & Director 1967 (58 anos)
Mr. Masayoshi Higuchi VP and Head of Quality, Regulatory Compliance Unit, Business Strategy & Compliance Dept.
Junichi Takano Head of Marketing & Sales Division

Endereço: Japan, Chuo, 2-1-1 Nihonbashi-Muromachi - abrir no Google Maps, abrir mapas Yandex
Site: https://www.chugai-pharm.co.jp